Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Even-skipped homeobox 2 (EVX2) is a homeobox transcription factor encoded by the EVX2 gene, located at the 5' end of the HOXD gene cluster on chromosome 2[1][3][5]. It is closely related to the Drosophila even-skipped (eve) gene, which is well-characterized as a pair-rule gene essential for segmental patterning during embryogenesis[2][4][5]. In humans, EVX2 functions as a sequence-specific DNA-binding transcription factor[5] and plays a critical role during limb and neural development. Microdeletions affecting EVX2 and adjacent HOXD genes can lead to limb malformations such as synpolydactyly (the fusion and duplication of digits)[1][5]. While EVX2 is crucial for development, there is currently no evidence supporting its direct involvement as a therapeutic target or its interaction with drugs[1][5]. Its functions mainly relate to development and morphogenesis, and alterations are associated with congenital disorders, not with acquired diseases like cancer or inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Even-skipped homeobox 2 (EVX2).